FENC
$7.76
Fennec Pharmaceuticals Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in ped...
Recent News
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -7.14% and +81.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
B Riley Reaffirms Fennec's Buy Rating, US$16.00 Price Target After Cipla Settlement
B. Riley reiterated its buy rating on the shares of Fennec Pharmaceuticals (FRX.TO, FENC) and its US
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State
Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This Year
This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands.
Payments Stock Down 30% Draws $6 Million Bet as Company Posts $4 Billion in Revenue
Euronet Worldwide runs a global payments platform, providing transaction processing and money transfer solutions across diverse markets.